Overview
- The ESMO presentation reported correct tissue‑of‑origin predictions in 92% of positive cases and detections skewed toward earlier stages, with 53.5% at stage I–II.
- Adding Galleri to usual screening was associated with more than a seven‑fold increase in cancers found within one year in a cohort of 23,161 asymptomatic adults in the U.S. and Canada.
- Most cancers detected by the test lacked existing routine screening options, according to study investigators and Grail executives.
- A U.K. symptomatic‑patient analysis found 35.4% of cases first labeled false positive were diagnosed with cancer within two years; Grail says including these cases could raise effective PPV to about 84%, a claim not yet peer‑reviewed.
- A large NHS implementation trial involving more than 140,000 people is still underway, with topline results expected in the middle of next year.